<DOC>
<DOCNO>EP-0640607</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2-Beta-alkenyl-penem-sulfonyl compounds as beta-lacterase inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31435	C07D49900	A61K3140	A61K31425	A61K31545	A61P4300	C07D49987	A61K31495	A61P3100	A61K31435	C07D499897	A61P3104	A61K31495	A61K31429	C07D49900	A61K31425	A61K31545	C07D49986	A61P4300	A61K3140	A61K31431	A61K3143	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	A61K	A61K	A61K	A61P	C07D	A61K	A61P	A61K	C07D	A61P	A61K	A61K	C07D	A61K	A61K	C07D	A61P	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D499	A61K31	A61K31	A61K31	A61P43	C07D499	A61K31	A61P31	A61K31	C07D499	A61P31	A61K31	A61K31	C07D499	A61K31	A61K31	C07D499	A61P43	A61K31	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to penem derivatives, especially to 3 beta -alkenyl-penem derivatives of the general formula 
<
IMAGE
>
  wherein   one of R
<
1
>
 and R
<
2
>
 is -COR
<
4
>
, -CN, -CH2R
<
5
>
, halogen, -CH=CHR
<
6
>
 or Q and the other is hydrogen or lower alkyl or both together are a gamma -lactam ring, R
<
3
>
 is hydrogen, lower alkyl, arylalkyl, allyl or a radical which can be removed in vivo, R
<
4
>
 is hydrogen, lower alkyl, lower alkoxy, benzyloxy, amino, lower alkylamino or lower alkyl-lower alkoxyamino, R
<
5
>
 is hydroxyl, -OCONHR
<
7
>
, -OCONH2 or a five- or six-membered heteroaromatic ring containing N, S and/or O and linked via a nitrogen atom,   R
<
6
>
 is -CN or -CHO,   R
<
7
>
 is COCH2Cl, Q is a five- or six-membered heteroaromatic ring containing N, S and/or O and   n is 0, 1 or 2,  and the pharmaceutically tolerable salts of these compounds. These compounds are good  beta -lactamase inhibitors. They can be used, if appropriate mixed with a  beta -lactam antibiotic, for the prevention or for the treatment of bacterial infections.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HUBSCHWERLEN CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
RICHTER HANS
</INVENTOR-NAME>
<INVENTOR-NAME>
SPECKLIN JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
HUBSCHWERLEN, CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
RICHTER, HANS
</INVENTOR-NAME>
<INVENTOR-NAME>
SPECKLIN, JEAN-LUC
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
3β-Alkenyl-penam derivatives of the general formula 

 
wherein
 
one of R
1
 and R
2
 signifies -COR
4
, -CN, -CH
2
R
5
, halogen, -CH=CHR
6
 
or Q and the other signifies hydrogen or C
1
-C
7
-alkyl or both 
together signify a γ-lactam ring, 


R
3
signifies hydrogen, C
1
-C
7
-alkyl, benzyl, benzhydryl, p-methoxybenzyl, 
p-nitrobenzyl, ally or a residue which is 

cleavable in vivo and which contains an ester group, such as 
-CH
2
OOCC(CH
3
)
3
, 

 
or -CH(CH
3
)OCO-CH
3
, 
R
4
signifies hydrogen, C
1
-C
7
-alkyl, C
1
-C
7
-alkoxy, benzyloxy, 
amino, C
1
-C
7
-alkylamino or C
1
-C
7
-alkyl-C
1
-C
7
-alkoxyamino, 
R
5
signifies hydroxy, -OCONHR
7
, -OCONH
2
 or a five- or six-membered 
hetero-aromatic ring which contains N,S and/or O 

and which is linked via a nitrogen atom, 
R
6
signifies -CN or -CHO, 
R
7
signifies -COCH
2
Cl, 
Q
signifies 2-pyridyl, 1-methyl-pyridin-2-ylio, 1,3-thiazol-2-yl, 
1,2,4-oxadiazol-3-yl and 
n
signifies 0, 1 or 2, 
 
as well as pharmaceutically compatible salts of these compounds. 
Compounds according to claim 1,
 
wherein
  
 

one of R
1
 and R
2
 signifies -COR
4
, -CN or -CH
2
R
5
 and the other 
signifies hydrogen or C
1
-C
7
-alkyl, 

R
3
signifies hydrogen, C
1
-C
7
-alkyl, benzyl, benzhydryl, p-methoxybenzyl, 
p-nitrobenzyl, allyl or a residue which is 

cleavable in vivo and which contains an ester group, such as 
-CH
2
OOCC(CH
3
)
3
, 

 
or -CH(CH
3
)OCO-CH
3
, 
R
4
signifies hydrogen, C
1
-C
7
-alkyl, C
1
-C
7
-alkoxy, benzyloxy, 
amino or C
1
-C
7
-alkylamino, 
R
5
signifies hydroxy or -CONH
2
 and 
n
signifies 0, 1 or 2. 
Compounds according to claim 1 or 2, wherein R
1
 
signifies CN, halogen or COR
4
, R
2
 signifies hydrogen and R
4
 
signifies methyl, C
1
-C
7
-alkoxy, benzyloxy or amino. 
Compounds according to any one of claims 1 to 3, 
wherein n signifies 0 or 2. 
Compounds according to any one of claims 1 to 4, 
wherein R
3
 signifies hydrogen or benzhydryl. 
The compound according to claim 1, benzhydryl (E/Z)-(2S,3S,5R)-3-(2-cyanoethenyl)-3-methyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
The compound according to claim 1, benzhydryl (E)-(2S,3S,5R)-3-(2-cyanoethenyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
The compound according to claim 1, benzhydryl (Z)-(2S,3S,SR)-3-(2-cyanoethenyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate.  

 
The compound according to claim 1, sodium (E)-(2S,3S,5R)-3-(2-cyanoethenyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
The compound according to claim 1, sodium (Z)-(2S,3S,5R)-3-(2-cyanoethenyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane
-2-carboxylate. 
The compound according to claim 1, sodium (E)-(2S,3S,5R)-3-(2-chloro-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
The compound according to claim 1, sodium (E)-(2S,3S,5R)-3-methyl-3-(3-oxo-but-1-enyl)-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
The compounds according to claim 1, benzhydryl (E/Z)-(2S,3S,5R)-3-(2-carbamoyl-vinyl)-3-methyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 


benzhydryl (E)-(2S,3S,5R)-3-(2-carbamoyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
benzhydryl (Z)-(2S,3S,5R)-3-(2-carbamoyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, 
sodium (E)-(2S,3S,5R)-3-(2-carbamoyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
sodium (Z)-(2S,3S,5R)-3-(2-carbamoyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
benzhydryl (E)-(2S,3S,5R)-3-(2-ethoxycarbonyl-vinyl)-3-methyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate,  

 
benzhydryl (E)-(2S,3S,5R)-3-(2-ethoxycarbonyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
sodium (E)-(2S,3S,5R)-3-(2-ethoxycarbonyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
benzhydryl (E)-(2S,3S,5R)-3-(2-benzyloxycarbonyl-vinyl)-3-methyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
benzhydryl (E)-(2S,3S,5R)-3-(2-benzyloxycarbonyl-vinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate, 
sodium (E)-(2S,3S,5R)-3-(2-benzyloxycarbonylvinyl)-3-methyl-4,4,7-trioxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate. 
Compounds of the general formula 

 
   wherein R
3
 has the significance given in claim 1. 
The compound according to claim 14, benzhydryl 
(2S,3R,5R)-3-formyl-3-methyl-7-oxo-4-thia-1-azabicyclo-[3.2.0]
heptane-2-carboxylate. 
Compounds according to any one of claims 1 to 13 for 
use as therapeutically active substances. 
Compounds according to any one of claims 1 to 13 for 
use as β-lactamase inhibitors.  

 
A process for the manufacture of compounds according 
to any one of claims 1 to 13, characterized by 


a) reacting a compound of the general formula 

 
   wherein R
3
 has the significance given in claim 1, 
with a compound of the general formula 


 
   wherein R
1
 and R
2
 have the significance given in claim 1
 
   and R
8
 signifies P
⊕
(aryl)
3
, PO(Oalkyl)
2
, Si(alkyl)
3
 or 
halogen,
 
in the presence of an activating agent, or 
b) oxidizing a compound of general formula I in which n 
signifies 0, or 
c) converting a compound of general formula I in which R
3
 is 
different from hydrogen into the corresponding free acid, and 
d) if desired, converting an acidic compound of formula I into a 
pharmaceutically acceptable salt. 
A medicament containing a compound according to any 
one of claims 1 to 13. 
A β-lactamase-inhibiting medicament containing a 
compound according to any one of claims 1 to 13. 
A medicament according to claim 19 or 20 which 
additionally contains a β-lactam antibiotic.  

 
A medicament according to claim 21 containing a 
penicillin, cephalosporin, penem or cabapenem as the β-lactam 

antibiotic. 
A medicament according to claim 22 containing 
piperacillin, mezlocillin, azlocillin, apalcillin, benzylpenicillin, 

phenoxymethylpenicillin, carbenicillin, methicillin, propicillin, 
ticarcillin, ampicillin, amoxicillin, mecillinam, ceftriaxone, 

ceftazidime, cefetamet, cefetamet pivoxil, cefotaxime, 
cefmenoxime, ceftizoxime, cefuroxime, cephaloridine, cephalotin, 

cefazolin, cephalexin, cefoxitin, cephacetrile, cefamandole, 
cephapirin, cephradine, cephaloglycine, cefpirone, cefepime, 

imipenem or meropenem or a pharmaceutically compatible salt of 
one of these compounds. 
A medicament according to claim 22 containing 
ceftriaxone or one of its pharmaceutically compatible salts. 
A medicament according to any one of claims 21 to 24 
as a combination preparation for the simultaneous, separate or 

chronologically stepwise use in antibacterial therapy. 
The use of compounds according to any one of claims 1 
to 13 for the manufacture of a medicament for the control or 

prevention of illnesses. 
The use of compounds according to any one of claims 1 
to 13 for the manufacture of a medicament for the control or 

prevention of bacterial infections. 
The use of compounds according to any one of claims 1 
to 13 for the manufacture of antibacterially-active medicaments. 
</CLAIMS>
</TEXT>
</DOC>
